Two Very Large Long Term Wall Street Analysts Now Agree: The Merck "Patent Cliff (In 2028)" Narrative Was Mostly Fear / Hype. 12 Mo. Target? $130, On NYSE.

Well. . . it is good to see that the high priced young MBAs on Wall & Broad are finally listening to the patent law experts: Merck will not have a crater event, in 2028 related to the pembrolizumab patents. As we've long said, the twice a year subcutaneous / injection version will. . . role out and extend through the mid-2030s minimum.

So now BMO has made Merck an "out-perform" in the pharma sector -- and raised its 12 month price target on the name. . . to $130. That's about a 30% forecasted return/gain, in a year. Sweet. BMO is right:

. . .[Merck was] upgraded by analysts at BMO Capital Markets from a "market perform" rating to an "outperform" rating in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has a $130.00 price objective on the stock, up from their previous price objective of $82.00. BMO Capital Markets' target price suggests a potential upside of 31.07% from the company's current price. . . .

[And last week, on] December 12, Morgan Stanley lifted its price target on Merck. . . to $102. . . . The firm kept an Equal Weight rating on the stock. In its 2026 outlook for the biopharma space, the firm said many of the policy concerns that weighed on the sector this year are likely to fade, allowing investors to shift their attention back to company fundamentals. . . .

Now you know. Onward. As we long said -- the cliff was always really just a. . . speed bump. Out.

नमस्ते